Quarterly revenues increased 10% on a reported basis and 13% at CER to $9.95 billion (£7.88 billion), beating the Zacks Consensus Estimate of $9.49 billion. The upside can be attributed to rising HIV and respiratory product sales, partially offset by the declining COVID-19 product sales. HIV sales rose 13%, driven by sales of new HIV drugs — Juluca, Dovato, Cabenuva and Apretude. Sales of the respiratory drug Nucala were up 17% during the quarter, driven by growth across the markets. General Medicines sales ...

Key Takeaways GSK lifted its sales and earnings projections for the year, after a strong performance by its HIV and cancer drugs drove second-quarter sales higher. The British pharmaceutical firm said sales rose 13% year-over-year to 7.88 billion pounds ($10.12 billion), beating analysts' estimates. GSK said it expects sales growth between 7% and 9% this year, up from its prior forecast, but cut its vaccine sales outlook. GSK (GSK) lifted its sales and earnings projections for the year, after a strong perfo ...

This quarterly report represents an earnings surprise of 9%. A quarter ago, it was expected that this drug developer would post earnings of $0.94 per share when it actually produced earnings of $1.09, delivering a surprise of 15.96%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. There are no easy answers to this key question, but one reliable measure that c ...

Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies Initial phase to identify and accelerate promising scientific concepts for further research starting in respiratory and immunology GSK and Flagship to jointly fund up to $150 million upfront GSK and Flagship will initially fund up to $150 million upfront to support an exploration phase to identify the most promising concepts for further research and development with Flagsh ...

In the past 30 days, GSK's earnings estimates have increased from $4.10 per share to $4.11 for 2024 and from $4.53 to $4.55 for 2025. | --- | --- | --- | --- | --- | |----------------------------------------------|-----------|-------|-----------|-----------| | Magnitude Consensus Estimate Trend (60 Days) | Q1 | Q2 | F1 | F2 | | Current | 1.00 | 1.27 | 4.11 | 4.55 | | 7 Davs A | 0.99 | 1.27 | 4.09 | 4.55 | | | | 1.28 | | | | | 0.99 0.99 | 1.28 | 4.10 4.10 | 4.53 4.52 | | | | | | | | | | | | | Zacks Investmen ...

GSK, a multinational pharma company, scans as a bargain. Prior to Walmsley's tenure, GSK grappled with significant hurdles, including the patent expiration of its respiratory blockbuster Advair, a weak oncology portfolio, and a limited pipeline beyond respiratory medicines. During her seven-year tenure, GSK has emerged as a formidable player in infectious diseases, solidified its leadership in respiratory ailments, and made promising strides in hematology/oncology through strategic acquisitions. GSK's stock ...

Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions. In other words, demand for healthcare and medications tends to be "inelastic," meaning that even if the costs of purchasing medications and healthcare services tick upward, demand is not likely to change substantively. This provides a stable revenue stream for pharmaceutical ...

GSK plc (GSK) boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development. In July 2022, GSK de-merged its Consumer Healthcare segment into a standalone company. The independent Consumer Healthcare company was named Haleon (HLN) . Haleon was a consumer health joint venture, an over-the-counter medicines business, jointly created by GSK and partner Pfizer (PFE) in 2019. GSK has been regularly selling its stake i ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the dosing of the first patient in GALAXIES Lung-301, a global, randomized, double-blind Phase 3 registrational clinical trial of belrestotug + dostarlimab versus placebo + pembrolizumab in patients with firstline advanc ...

Jemperli is currently approved for use in combination with standard-of-care chemotherapy combination, carboplatin and paclitaxel for treating adult patients with primary advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability-high in Europe. Shares of GSK have rallied 9.2% so far this year against the industry's decline of 5.8%. Jemperli is a key drug that aids GSK's oncology sales. The drug generated sales worth £80 million in the first quarter of 202 ...